The level of endogenous DNA damage in lymphocytes isolated from blood is associated with the fluctuation of 17β-estradiol concentration in the follicular phase of healthy young women.

• Authors: Maria Kapiszewska , Malgorzata Kalemba , Aneta Grzesiak , Kinga Kocemba
• Languages of publication: EN

Abstracts

EN

The aim of this study was to evaluate whether the differences in plasma 17β-estradiol concentration in early and late follicular phases of the menstrual cycle can affect the level of endogenous DNA damage in lymphocytes assessed by comet assay, and whether the extent of this damage in the follicular phase is associated with the genotype of catechol-O-methyltransferase (COMT). The level of DNA damage was positively correlated with 17β-estradiol concentration only in the late follicular phase. Subjects with the COMT L/L homozygous mutated variant revealed more DNA damage as compared to individuals with the COMT wild-type and heterozygous (H/L+HH) genotype.

Keywords

EN

endogenous DNA damage; catechol-O-methyltransferase (COMT); comet assay; 17β-estradiol

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2005
• Volume: 52
• Issue: 2
• Pages: 535-539

Dates

published

2005

received

2005-04-05

revised

2005-05-19

accepted

2005-06-03

(unknown)

2005-06-20

Contributors

author

Maria Kapiszewska

• Department of General Biochemistry, Faculty of Biotechnology, Jagiellonian University, Krakow, Poland

author

Malgorzata Kalemba

• Department of General Biochemistry, Faculty of Biotechnology, Jagiellonian University, Krakow, Poland

author

Aneta Grzesiak

• Department of General Biochemistry, Faculty of Biotechnology, Jagiellonian University, Krakow, Poland

author

Kinga Kocemba

• Department of General Biochemistry, Faculty of Biotechnology, Jagiellonian University, Krakow, Poland

References

• Abd-Allah GA, el-Fayoumi RI, Smith MJ, Heckmann RA, O’Neill KL (1999) Mutat Res 446: 181-188.
• Abrahamse SL, Pool-Zobel BL, Rechkemmer G (1999) Carcinogenesis 20: 629-634.
• Anderson D (2001) Mutat Res 480-481: 337-347.
• Anderson D, Phillips BJ, Yu TW, Edwards AJ, Ayesh R, Butterworth KR (1997) Environ Mol Mutagen 30: 161-174.
• Beani JC (2001) Bull Acad Natl Med 185: 1507-1525.
• Betancourt M, Ortiz R, Gonzalez C, Perez P, Cortes L, Rodriguez L, et al (1995) Mutat Res 331: 65-77.
• Brannstrom M, Mayrhofer G, Robertson SA, (1993) Biol Reprod 48: 277-286.
• Buschfort C, Muller MR, Seeber S, Rajewsky MF, Thomale J (1997) Cancer Res 57: 651-658.
• Casey ML, MacDonald PC (1983) Am J Obstet Gynecol 145: 453-457.
• Collins AR, Dusinska M, Gedik CM, Stetina R (1996) Environ Health Perspect 104: Suppl 3, 465-469.
• Cutolo M, Seriolo B, Villaggio B, Pizzorni C, Craviotto C, Sulli A (2002) Ann NY Acad Sci 966: 131-142.
• Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, et al (2004) Lupus 13: 635-638.
• Dusinska M, Vallova B, Ursinyova M, Hladikova V, Smolkova B, Wsolova L, Raslova K, Collins AR (2002) Food Chem Toxicol 40: 1119-1123.
• Fenech M (2001) Mutat Res 475: 57-67.
• Giovannelli L, Saieva C, Masala G, Testa G, Salvini S, Pitozzi V, et al (2002) Carcinogenesis 23: 1483-1489.
• Gonzalez C, Najera O, Cortes E, Toledo G, Lopez L, Betancourt M, et al (2002) Teratog Carcinog Mutagen 22: 147-158.
• Goodman JE, Lavigne JA, Wu K, Helzlsouer KJ, Strickland PT, Selhub J, Yager JD (2001) Carcinogenesis 22: 1661-1665.
• Hartmann A, Plappert U, Raddatz K, Grunert-Fuchs M, Speit G (1994) Mutagenesis 9: 269-272.
• Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY (1999) Cancer Res 59: 4870-4875.
• Kapiszewska M, Zajac G, Kalemba M, Soltys E (2005) J Pharmac Physiol 56: Suppl 1, 199-217.
• Kapiszewska M, Kalemba M, Wojciech U, Milewicz T (2005a) J Nutr Biochemistry (in press).
• Lang TJ (2004) Estrogen as an immunomodulator. Clin Immunol 113: 224-230.
• Lavigne JA, Helzlsouer KJ, Huang HY, Strickland PT, Bell DA, Selmin O, et al (1997) Cancer Res 57: 5493-5497.
• Levitt M, Hunter C, Baron M (1982) Neuropsychobiology 8: 276-279.
• Li SA, Purdy RH, Li JJ (1989) Carcinogenesis 10: 63-67.
• Liehr JG (1997) Eur J Cancer Prev 6: 3-10.
• Liehr JG (2000) Endocr Rev 21: 40-54.
• Martin FL, Cole KJ, Harvey D, Weaver G, Williams JA, Millar BC, et al (2000) Carcinogenesis 21: 799-804.
• Matsui A, Ikeda T, Enomoto K, Hosoda K, Nakashima H, Omae K, Watanabe M, Hibi T, Kitajima M (2000) Cancer Lett 151: 87-95.
• Mayne ST (2003) J Nutr 133: Suppl 3: 933S-940S.
• Nissinen E (1985) Anal Biochem 144: 247-522.
• Nissinen E, Tuominen R, Perhoniemi V, Kaakkola S (1988) Life Sci 42: 2609-2614.
• Olinski R, Jaruga P, Zastawny TH (1998) Acta Biochim Polon 45: 561-572.
• Peluso M, Airoldi L, Magagnotti C, Fiorini L, Munnia A, Hautefeuille A, Malaveille C, Vineis P (2000) Carcinogenesis 21: 183-187.
• Porrini M, Riso P, Oriani G (2002) Eur J Nutr 41: 95-100.
• Puhakka A, Ollikainen T, Soini Y, Kahlos K, Saily M, Koistinen P, et al (2002) Mutat Res 514: 7-17.
• Raftogianis R, Creveling C, Weinshilboum R, Weisz J (2000) J Natl Cancer Inst Monogr 27: 113-124.
• Rosales AL, Cunningham JM, Bone AJ, Green IC, Green MH (2004) Free Radic Res 38: 665-674.
• Salem ML (2004) Curr Drug Targets Inflamm Allergy 3: 97-104.
• Sardas S, Yilmaz M, Oztok U, Cakir N, Karakaya AE (2001) Mutat Res 490: 123-129.
• Singh NP, McCoy MT, Tice RR, Schneider EL (1988) Exp Cell Res 175: 184-191.
• Szeto YT, Collins AR, Benzie IF (2002) Mutat Res 500: 31-38.
• Thompson PA, Ambrosone C (2000) J Natl Cancer Inst Monogr 27: 125-134.
• Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF (2000) Environ Mol Mutagen 35: 206-221.
• White KL, Chalmers DM, Martin IG, Everett SM, Neville PM, Naylor G (2002) Br J Nutr 88: 265-271.
• Wolf FI, Torsello A, Covacci V, Fasanella S, Montanari M, Boninsegna A, et al. (2002) Exp Gerontol 37: 647-656.